Institute of Pharmaceutical Research, GLA University, Mathura, 281406, India.
Med Oncol. 2023 Apr 25;40(6):159. doi: 10.1007/s12032-023-02020-x.
Colorectal cancers are among the most commonly found cancers over the world. In spite of the recent advancements in diagnosis and prognosis, the management of this metastatic condition remains a challenge. The utility of monoclonal antibodies in the healing of patients with colorectal cancer has opened a new chapter in the quest for newer therapies. The resistance to the standard treatment regimen made it mandatory to search for newer targets. Mutagenic alterations in the gene engaged in cellular differentiation and growth pathway have been the reason for resistance to treatment. The newer therapies target the various proteins and receptors involved in the signal transduction and down streaming pathways leading to cell proliferation. This review presents an insight into the newer targeted therapies for colorectal cancer involving tyrosine kinase blockers, epidermal growth factor receptors, vascular endothelial growth factor, immune checkpoint therapy, and BRAF inhibitors.
结直肠癌是世界上最常见的癌症之一。尽管最近在诊断和预后方面取得了进展，但这种转移性疾病的治疗仍然是一个挑战。单克隆抗体在治疗结直肠癌患者中的应用为寻求新的治疗方法开辟了新篇章。对标准治疗方案的耐药性使得寻找新的靶点成为必要。参与细胞分化和生长途径的基因发生突变改变是治疗耐药的原因。新的治疗方法针对参与信号转导和下游途径导致细胞增殖的各种蛋白质和受体。这篇综述介绍了涉及酪氨酸激酶抑制剂、表皮生长因子受体、血管内皮生长因子、免疫检查点治疗和 BRAF 抑制剂的结直肠癌的新型靶向治疗。
